King County Navigation Bar (text navigation at bottom)
Public Health - Seattle & King County
Site Directory

Public Health Webpage Directory

Public Health Center & Office Locations

For Care Providers

Health Advisories & Resources

For Educators

Health Educators Toolbox

About Us

History & Profile

Jobs

Employee Directory

Contact Us

Public Health
Seattle & King County
401 5th Ave., Suite 1300
Seattle, WA 98104

Phone: 206-296-4600
TTY Relay: 711

Click here to email us

Subscribe to Free Email Alerts!

Click here to learn more

magnifying glass Advanced Search
Search Tips
Home » Epi-Log Newsletter » June 2005

The Epi-Log Newsletter
Volume 45, No. 6 - June 2005

Adobe Acrobat Reader icon This issue is available in Adobe Acrobat PDF format

green square bullet
Survey of Hepatitis C Patient Needs
green square bullet
Pertussis Vaccine Approved for Adolescents and Adults
green square bullet CDC Immunization Update July 28th
green square bullet Erratum

green square bullet
Communicable Disease and Epidemiology contact information
green square bullet Reported Cases of Selected Diseases in Seattle and King County

Survey of Hepatitis C Patient Needs

Although formal recommendations have been issued by CDC for preventing progression of liver disease and treatment for patients with chronic hepatitis C infection (HCV), little is known about the needs of HCV-infected persons in King County . In 2004, Public Health-Seattle & King County performed a needs assessment of persons who were reported with chronic HCV to identify priority areas for public health interventions.

Between January 1, 2002 and July 1, 2003, 2,475 persons diagnosed with chronic HCV were reported to Public Health. A standardized questionnaire was administered to a random sample (906) of this group, and to a convenience sample of 21 adults incar-cerated in the King County Jail during the same time period.

A total of 197 persons completed the questionnaire (180/906 non-incarcerated and 17/21 incarcerated).  Ninety-two percent were aware of their HCV infection. Of those, 12 percent were tested in a public clinic, 55 percent in a private clinic or office, 9 percent in a blood bank, and 6 percent in jail or prison. The most common reasons for being tested for HCV were abnormal liver function tests or symptoms (34 percent), and participation in a program that routinely screens for HCV (19 percent). The remaining 47 percent were screened for other reasons, including routine physicals, life insurance exams, a known exposure, or high risk behavior.

Eighty-four percent of persons diagnosed with HCV visited a health care professional after diagnosis. Of these:

  • 58 percent reported being counseled to avoid hepatotoxic medications
  • 54 percent recalled being offered vaccination for hepatitis A or B
  • 47 percent were told to avoid alcohol; and,
  • 35 percent were treated for their HCV infection.

Thirty-one percent of persons reported that they had not received adequate information about chronic HCV in order to make decisions about managing their condition. Incarcerated persons were more likely than non-incarcerated persons to report being told that nothing could be done for their HCV infection (35 percent vs. 6 percent).

On the basis of these data, we conclude that persons with chronic HCV infection need improved access to information about their disease including measures to prevent progression of disease (including vac-cination for hepatitis B and C), and treatment considerations.

The Hepatitis Education Project is a good local resource where healthcare professionals can refer persons with hepatitis C and their families. The mission of the Hepatitis Education Project is to educate patients, medical personnel and the public about hepatitis C and to provide resources to help those living with HCV disease. In addition to providing educational materials, they also sponsor support groups, publish a newsletter, and provide a drop-in center in Seattle. For more information about the Hepatitis Education project, see their website at www.hepeducation.org, or call (206) 732-0311.

Additional information about hepatitis C can be found at:

www.metrokc.gov/health/prevcont/hepcfactsheet.htm
www.cdc.gov/ncidod/diseases/hepatitis/c

Pertussis Vaccine Approved for Adolescents and Adults

FDA Approves a New Combination Vaccine to Help Protect Both Adolescents and Adults against Whooping Cough

On June 10th, 2005, the Food and Drug Adminis-tration (FDA) approved a new vaccine for a single booster immunization against pertussis (whooping cough), in combination with tetanus and diphtheria, for adolescents and adults 11-64 years of age. The vaccine will be marketed as Adacel by Aventis Pasteur Limited located in Toronto, Canada. Adacel is the first vaccine approved as a pertussis booster for adults. Vaccines for prevention of tetanus and diphtheria (Td vaccine) in adolescents and adults have been available for many years.

Recently, FDA approved a similar vaccine called Boostrix, manufactured by GlaxoSmithKline, for use in adolescents 10-18 years of age.

Pertussis is a highly communicable illness in adolescents and adults, and can cause prolonged cough and missed days at school and work. In young infants, who are too young to be fully vaccinated, pertussis is often severe and can be fatal. Since 1980, the rates of reported pertussis cases have been increasing in adolescents and adults, as well as in young infants. Adolescents and adults have been implicated as the source of pertussis infection for susceptible young infants, and other family members.

Recommendations for pertussis immunization in adolescents and adults are scheduled for discussion at the June 29-30, 2005 meeting of the Advisory Committee on Immunization Practices (ACIP), after which formal recommendations may be issued by the CDC.

^ back to top

CDC Immunization Update July 28th

CDC’sImmunization Update 2005” will be shown via live satellite broadcast from 8:30 AM to 11:30 AM on July 28th at  the Blanchard Plaza Building on 6th and Blanchard in downtown Seattle . The presentation may also be viewed via live webcast on July 28th from 6 to 8:30 AM, and again from 9 to 11:30 AM at: www.phppo.cdc.gov/phtn/webcast/immup2005

This “Immunization Update” will provide up-to-date information on the rapidly changing field of immunization. Anticipated topics include new recommendations for influenza vaccine, an update of the influenza vaccine supply, meningococcal conjugate vaccine, acellular pertussis vaccine for adolescents, and revised varicella vaccine recommendations.

Continuing education (CE) credit will be offered for both the satellite and web broadcasts. Details on CE credit can be found at www.cdc.gov/nip/ed/ce.htm.

Can’t watch it on July 28th? Four to six weeks after the broadcast, this course (along with other archived immunization courses) will be available for self-study via the web at: www.cdc.gov/nip/ed

To order a registration form for the in-person satellite broadcast, call Maybelle Tamura at (206) 296-5252 (subscribers to The VacScene newsletter will automatically receive a registration form in the mail).

Erratum

In the May 2005 issue of the EPI-LOG, we incorrectly stated that Washington State had not detected an animal infected with West Nile Virus since 1992. The correct year was 2002.

Communicable Disease and Epidemiology contact information

> Disease reporting

AIDS (206) 296-4645
Sexually Transmitted Diseases (206) 744-3954
Tuberculosis (206) 744-4579
Other Communicable Diseases (206) 296-4774
Automated 24-hour reporting line for conditions not immediately notifiable (206) 296-4782

> Hotlines

Communicable Disease Hotline (206) 296-4949
HIV/STD Hotline (206) 205-7837

> For health providers:

  • Health Provider homepage
    Resources to fact sheets, updated news, vaccine information, health educational materials and external links.
    www.metrokc.gov/health/providers

Reported Cases of Selected Diseases in Seattle and King County


Cases reported
in May
Cases reported through May
 
2005
2004
2005
2004
Campylobacteriosis
27
21
111
90
Cryptosporidiosis
9
1
40
11
Chlamydial infections
409
468
2,332
2,055
Enterohemorrhagic
E. coli (non-O157)
0
0
3
0
E. coli O157: H7
3
6
12
9
Giardiasis
8
9
43
51
Gonorrhea
147
95
661
472
Hæmophilus influenzæ (cases <6 years of age)
1
0
1
2
Hepatitis A
2
0
8
3
Hepatitis B (acute)
4
1
11
14
Hepatitis B (chronic)
72
68
258
272
Hepatitis C (acute)
1
0
4
5
Hepatitis C (chronic, confirmed/probable)
118
129
528
568
Hepatitis C (chronic, possible)
33
26
198
149
Herpes, genital (primary)
22
86
252
294
HIV and AIDS (includes only AIDS cases not previously reported as HIV)
41
28
209
180
Measles
0
0
0
6
Meningococcal Disease
0
1
10
9
Mumps
0
0
1
0
Pertussis
39
19
102
100
Rubella
0
0
1
0
Rubella, congenital
0
0
0
0
Salmonellosis
23
16
89
77
Shigellosis
4
3
26
30
Syphilis
7
10
66
39
Syphilis, congenital
0
0
0
0
Syphilis, late
4
6
34
31
Tuberculosis
6
6
42
48

Updated: Monday, June 27, 2005 at 02:03 PM

All information is general in nature and is not intended to be used as a substitute for appropriate professional advice. For more information please call 206-296-4600 (voice) or 206-296-4631 (TTY Relay service). Mailing address: ATTN: Communications Team, Public Health - Seattle & King County, 401 5th Ave., Suite 1300, Seattle, WA 98104 or click here to email us.

King County | Public Health | News | Services | Comments | Search

Links to external sites do not constitute endorsements by King County.
By visiting this and other King County web pages, you expressly agree to be bound by terms
and conditions of the site. The details.